KRT17 and endometrial cancer: In patients with high-grade endometrial cancer, high expression levels of KRT17 mRNA was associated with decreased OS, with a median survival of 4.2 years for high expression of KRT17 mRNA and 9.2 years for low expression of KRT17 mRNA.